Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

OBJECTIVES: Primary * To evaluate the effect of erlotinib and stereotactic body radiotherapy on 6-month progression-free survival of patients with locally advanced or metastatic non-small cell lung cancer. Secondary * To describe the actuarial rate of in-field local control and out-of-field disease progression in patients treated with this regimen. * To evaluate the safety of this regimen in these patients. * To evaluate overall survival of patients treated with this regimen. * To evaluate the duration of erlotinib usage and time to initiation of third-line systemic therapy (chemotherapy or biologic agent) in these patients. OUTLINE: This is a multicenter study. Patients receive oral erlotinib hydrochloride once daily in the absence of disease progression or unacceptable toxicity. Beginning 1-4 weeks after the initiation of erlotinib hydrochloride, patients undergo stereotactic body radiotherapy. After completion of study treatment, patients are followed every 3 months.